Top 10 PBM Industry Macrotrends in 2019 & What to Expect in 2020 The PBM industry saw some significant changes in 2019, as some of the largest forces in the market vertically integrated and began implementing...
In DRG Blog, Market Access/ January, 2020 Cell and Gene Therapies: Five Key Access and Reimbursement Strategies Cell and gene therapies are revolutionizing the field of medicine by offering life-changing benefits to people with rare diseases and cancers...
In DRG Blog, Market Access/ October, 2019 Building A Market Access Advantage During Early Stage Development How can pharma companies build market access advantage during early stage development? The market access environment in the US has become tougher...
In DRG Blog, Market Access/ June, 2019 Will the Institute for Clinical and Economic Review Evolve as a formal HTA body in the US? Growing role of ICER in the value-driven healthcare system The U.S. healthcare system is unique in many ways, with one key differentiator being the...
In DRG Blog, Market Access/ November, 2018 How Pfizer’s Decision to Halt Price Impacts the Healthcare Industry President Donald Trump has made no secret his disapproval of unreasonable price increases implemented by pharma companies. The feud between pharma...
In DRG Blog, Market Access/ August, 2018 The evolving PBM market – trends to watch Amidst mergers, alliances and increased scrutiny, PBMs face a season of change With 2017 receding into the rearview mirror, the road ahead for PBMs...
In DRG Blog, Market Access/ March, 2018 As Congress Dithers, States Take the Lead on Drug Pricing Initiatives Push for Transparency Adds Pressure on Pharmacy Benefit Managers (PBM) and Pharma Repeal and replace may be dead for now, but the debate over...
In DRG Blog, Market Access/ September, 2017 Formulary exclusions set up contentious environment for pharma companies In an aggressive move to counteract the financial impact of expensive medications, CVS Health has excluded 154 products from its standard formulary...
In DRG Blog, Market Access/ September, 2016 Weighing the cost: PBMs take different approaches to PCSK-9 inhibitors Every once in a while, a pharmaceutical breakthrough comes along that drastically changes the way a particular disease or a condition is treated...
In DRG Blog, Market Access, Drug Watch/ June, 2016 
